In a remarkable humanitarian initiative, the 14th edition of the free Plastic Surgery Camp, organized by Akums, in collaboration with Rotary International Club and Interplast Germany, has once again ignited hope among hundreds of underserved patients
Eli Lilly and Company (India) Pvt. Ltd. has obtained CDSCO marketing approval for donanemab. The medication provides an alternative therapy to adults experiencing early symptomatic Alzheimer disease...
Pfizer has introduced Rimegepant, a calcitonin gene-related peptide treatment for migraine, marking a notable expansion of its neuroscience portfolio in India. The company said the 75 mg orally disintegrating tablet is designed for adults who need...
WHO diabetes pregnancy guidelines published today are a significant change to the way the healthcare systems focus on a condition that occurs in one per six pregnancies across the globe. Approximately 21 million women are vulnerable to risks...
AstraZeneca Pharma India and Sun Pharmaceutical Industries have struck a second brand partnership to broaden access to sodium zirconium cyclosilicate (SZC), a critical therapy for hyperkalaemia, across India. Under this deal, AstraZeneca will...
Alembic Pharmaceuticals experienced an increase of 3.07%, reaching Rs 930.50, following the announcement that it has obtained final approval from the USFDA for its ANDA concerning Diltiazem Hydrochloride tablets
OMRON Healthcare Co., Ltd. has revealed further investment in the India-focused AI medtech startup TRICOG HEALTH INDIA PRIVATE LIMITED
Following the historic approval granted in August 2025 by India’s Central Drugs Standard Control Organization (CDSCO), Shilpa Medicare has launched NODUCA (Nor Ursodeoxycholic Acid, or norUDCA), the first medication of its kind to be introduced in
Sanofi’s type?1 diabetes therapy Teizeild (teplizumab) has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use. This makes Teizeild the first disease-modifying therapy to type 1 diabetes...
Zydus Lifesciences receives final USFDA approval for its Leuprolide Acetate injection, the generic version of Lupron, used in the palliative treatment of advanced prostate cancer. The approval strengthens Zydus’s oncology portfolio in the US market.